First Allied Advisory Services’s Denali Therapeutics DNLI Stock Holding History

First Allied Advisory Services’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-21,950	Closed	-$531K	–	1188
2020 Q2	$531K	Hold	21,950	–	–	0.02%	636
2020 Q1	$384K	Hold	21,950	–	–	0.02%	678
2019 Q4	$380K	Buy	21,950 +3,000	+16%	+$49.9K	0.01%	818
2019 Q3	$292K	Buy	+18,950	New	+$362K	0.01%	907

Other funds holding DNLI

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Allied Advisory Services's DNLI Position: Q3 2020 in Review

First Allied Advisory Services sold out of Denali Therapeutics (DNLI) in Q3 2020, closing a stake of 21,950 shares — an estimated $531K sold.

First Allied Advisory Services first reported a position in DNLI in Q3 2019 and held it in 4 quarters. The position peaked at $531K in Q2 2020. 170 funds tracked by Wall St. Rank hold DNLI as of Q3 2020.

First Allied Advisory Services reported no remaining Denali Therapeutics position as of Q3 2020 after selling out during the quarter.
First Allied Advisory Services sold 21,950 Denali Therapeutics shares in Q3 2020, an estimated $531K.
First Allied Advisory Services first reported a position in Denali Therapeutics in Q3 2019 and held it in 4 quarters.
First Allied Advisory Services's Denali Therapeutics position peaked at $531K in Q2 2020.
170 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2020.

Based on First Allied Advisory Services's 13F filing for Q3 2020, filed 13 Nov 2020.